Intriguingly, SGLT2 inhibitors were recently found to beyond glucose lowering that included potential renoprotective and cardiovascular benefits in patients with and without T2DM (Perkovic et al., 2019; Heerspink et al., 2020). Here, SLC5A2 is linked to type 2 diabetes mellitus.